PowerEase Touch 600W Power Supply.
Our newest cell and protein biology products and technologies
Updated April 2022
On this page:
Western workflow
- Introducing the PowerEase Touch 600W Power Supply—more power for more applications
- Protein gels welcome packs for protein expression analysis
Cell analysis and imaging
- Electronic records software available for Countess 3 and Countess 3 FL Automated Cell Counters
- Convenient reference slide for Countess 3 and Countess 3 FL Automated Cell Counters
- Enhanced imaging experience with EVOS Optimized Light Cubes
- Celleste 6 Image Analysis Software—now available for EVOS M5000 and EVOS M7000 Imaging Systems
Antibodies
- Myelin-oligodendrocyte glycoprotein antibody for neuroinflammatory disease research
- Antibodies against the receptor ITGB1
- Antibodies for studying the role of MIF in inflammatory response and angiogenesis
Immunoassays
Nucleic acid quantification
The Invitrogen PowerEase Touch 600W Power Supply joins the PowerEase Touch 120W and 350W Power Supplies, adding another level of power and enabling users to conduct isoelectric focusing experiments (Table 1).
Like its siblings, the PowerEase Touch 600W Power Supply has a bright, LCD touchscreen interface, which provides easy entry of up to 100 custom programs, or selection of preprogrammed protocols for Invitrogen protein gels and gel transfers.
Table 1. Comparison of PowerEase Touch Power Supply models.
| Features of PowerEase models | 120W (basic) | 350W (high current) | 600W (universal) |
|---|---|---|---|
| Mini gel runs | 4 | 12 | 12 |
| Mini gel transfers | 2 | 8 | 8 |
| Midi gel runs | 2 | 8 | 8 |
| Midi gel transfers | No | 4 | 4 |
| Isoelectric focusing (IEF) gels | No | No | Yes |
| Power output | 1–120 W | 1–350 W | 1–600 W |
| Current output | 1–500 mA | 1 mA–3 A | 1 mA–3 A |
| Voltage output | 2–300 V | 2–300 V | 2–500 V |
Explore our complete selection of electrophoresis power supplies, including the PowerEase Touch 600W Power Supply
Two money-saving protein gels welcome packs have been designed for use with any protein expression application—such as transient protein production using the Gibco Expi293 Expression System—enabling you to analyze your expression results quickly and easily. These welcome packs provide all necessary gels, buffers, and reagents as well as a fast 12-minute gel stain to visualize electrophoresis results. An Invitrogen gel tank is included at essentially no extra cost.
The gels provided in the Invitrogen Bolt Mini Bis-Tris Welcome Pack and the Invitrogen NuPAGE Midi Bis-Tris Welcome Pack can be run in as little as 20–35 minutes and stained in only 12 minutes.
Key benefits:
- Protein resolution—the 4–12% polyacrylamide gradients of the Bolt Mini Bis-Tris Plus gels (12-well) and the higher-throughput NuPAGE Midi Bis-Tris gels (20-well) deliver sharp, well-resolved bands
- Rapid time-to-results—Bolt Mini Bis-Tris Plus gels can be run in 20 minutes, and NuPAGE Midi Bis-Tris gels can be run in 35 minutes; quick, 12-minute staining protocol using Invitrogen SimplyBlue SafeStain
- Convenience—the Invitrogen Mini Gel Tank offers easy, side-by-side sample loading into the larger-volume, wedge-shaped wells of the Bolt Mini Bis-Tris Plus gels; run up to 40 samples in the Invitrogen SureLock Tandem Midi Gel Tank, or purchase 26-well gels for even higher throughput
- Two-in-one gel tank included at no extra cost—perform wet tank protein transfers for western blot analysis in the same tank at room temperature with the purchase of separately available blot modules
Learn more about the protein gel welcome packs
Bolt Mini Bis-Tris Welcome Pack for Protein Expression (4–12%, 12-well).
NuPAGE Midi Bis-Tris Welcome Pack for Protein Expression (4–12%, 20-well).
Invitrogen Countess 3 and Countess 3 FL Automated Cell Counters have updated software features that include the ability to support 21 CFR Part 11 compliance. This FDA requirement addresses the transition from paper record keeping to electronic record keeping. The Countess 3 and Countess 3 FL Automated Cell Counters use security, audit, and electronic signature (SAE) software to support electronic record keeping compliance. The purchase of a license key (Cat. No. A51025) unlocks the SAE mode on the Countess 3 instrument and allows customers to connect the instrument to their SAE server.
Additionally, updated features in the latest software update include refined FCS file reporting (enabling greater usability), optimized lighting settings, and expanded profile functions, including saving preferred dilution settings. These features are all freely accessible via software download and instrument update.
Learn more about Countess 3 Automated Cell Counters
Countess 3 and Countess 3 FL Automated Cell Counters.
The Invitrogen Countess 3 Standard Slide is a reference slide that complements the Countess 3 and Countess 3 FL Automated Cell Counters. It is a ready-to-use slide that contains permanently mounted microspheres in a cell counting chamber. Cell counts from the standard slide are consistent from one Countess instrument to the next. The microspheres mimic the appearance of a 1:1 mixture of live and dead cells stained with trypan blue solution when counted in brightfield mode (Figure 1). When used in fluorescence mode, the microspheres provide approximately 50% detection with Invitrogen EVOS DAPI and GFP light cubes and approximately 50% detection with Invitrogen EVOS RFP, Texas Red, and Cy®5 light cubes (Figure 1).
Uses and benefits of the Countess 3 Standard Slide:
- Confirmation—use as a counting and viability standard
- Reproducible—permanently mounted microspheres minimize variability from one count to the next
- Convenient—ready-to-use and reusable
Find out more about our selection of Countess Automated Cell Counter accessories
Figure 1. Brightfield (top) and fluorescence (bottom) counts using the Countess 3 Standard Slide each with approximately 50/50 live/dead or blue/red ratios.
Invitrogen EVOS and Invitrogen Countess second-generation LED light cubes (2.0) take cell imaging to the next level for even better publication-quality images. These interchangeable light cubes deliver precise control and plug-and-play capability.
Features of the optimized light cubes include:
- Improved opto-mechanical design
- More uniform illumination across field of view (FOV)
- Spectrally optimized optical components
- Improved spectral fidelity across channels to eliminate undesired bleed-through
- Maximized signal-to-background ratio even with dim samples
- Compatible with legacy EVOS Light Cubes and Invitrogen Countess FL Automated Cell Counters
Choose the right EVOS LED light cubes for your experiments using the Light Cube Selector
Learn more about EVOS LED light cubes and other EVOS Cell Imaging System accessories
EVOS LED Light Cubes. EVOS Light Cube, Cy5.5 2.0 and EVOS Light Cube, TagBFP 2.0.
Invitrogen Celleste 6 Image Analysis Software is a full-featured image analysis suite designed for biological applications that enables users of the Invitrogen EVOS M5000 and EVOS M7000 Imaging Systems to seamlessly capture, process, segment, classify, measure, analyze, and share images and data.
The multi-channel analysis (MCA) tool featured in version 6 utilizes preconfigured algorithms and analysis templates, which have been trained on representative data, to optimally segment and classify images from a range of common cell-based assays. Simply choose the app that corresponds to your assay of interest and follow the wizard-based workflow steps from image to data generation. Bio applications include cell viability, apoptosis, cell cycle, live/dead cell analysis, transfection efficiency, immunohistochemistry analysis, migration tracking, wound healing, adipogenesis, and cytoskeletal disruption.
Learn more about the Celleste 6 Image Analysis Software
Celleste 6 Image Analysis Software.
Myelin-oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a minor myelin protein expressed on the outer surface of myelin sheaths and oligodendrocytes. It is expressed primarily within the brain, spinal cord, and the optic nerves. Due to its localization, MOG is a potential target of immune-mediated demyelination and has been regarded as a putative autoantigen in individuals with inflammatory demyelinating diseases.
Antibodies against MOG act as specific biomarkers for a subset of acquired demyelinating syndromes known as myelin-oligodendrocyte glycoprotein antibody–associated diseases (MOGAD). These antibodies are detected in individuals with optic neuritis, myelitis, opticomyelitis, and acute or multiphasic disseminated encephalomyelitis (ADEM/MDEM) but not in individuals with multiple sclerosis (MS). MOG antibodies serve as an important marker for oligodendrocyte maturation attributable to its expression in the later stages of myelinogenesis. Antibodies that are functionally verified for specificity can help provide confidence in disease research (Figure 2).
Learn more about Invitrogen antibody validation
Search our entire inventory of Invitrogen antibodies using our antibody search tool
Figure 2. Specificity of the MOG antibody shown by relative expression in a western blot where MOG is detected distinctively in brain and cerebellum tissue extracts and not in heart or liver. Western blot analysis was performed using the Invitrogen MOG Recombinant Rabbit Monoclonal Antibody (clone JM23-06) (Cat. No. MA5-32857), and a 27 kDa band corresponding to MOG was observed specifically in brain and cerebellum tissues. Extracts of the indicated tissue (30 μg lysate) were electrophoresed on an Invitrogen NuPAGE 10% Bis-Tris Mini Protein Gel (Cat. No. NP0301BOX). Resolved proteins were then transferred onto an Invitrogen iBlot 2 Transfer Stack, nitrocellulose membrane (Cat. No. IB23001), using the Invitrogen iBlot 2 Gel Transfer Device (Cat. No. IB21001). The blot was probed with the primary antibody (1:5,000 dilution) and detected by chemiluminescence with the Invitrogen Goat Anti–Rabbit IgG (H+L), Superclonal Recombinant Secondary Antibody, HRP (Cat. No. A27036, 1:4,000 dilution), using the Invitrogen iBright FL1500 Imaging System (Cat. No. A44115). Chemiluminescent detection was performed using the Thermo Scientific Pierce ECL Western Blotting Substrate (Cat. No. 32106).
Interactions of cells amongst each other and with the extracellular environment are mediated by different families of receptors. In addition to mediating cell adhesion and motility, these receptors guide many cellular processes including growth and differentiation. A growing body of evidence also suggests that these proteins help facilitate the development and progression of cancer, whereby alterations in their expression may bring about tumor malignancy, invasiveness, and metastasis. Integrins are a family of transmembrane receptors that have roles in cell cycle regulation, cytoskeleton organization, and recruitment of new receptors to the cell membrane. They work in conjunction with proteins such as cadherins, selectins, and syndecans to mediate cell–cell and cell–matrix interactions.
Integrin beta-1 (ITGB1 or CD29) belongs to a class of integrins that bind to collagen. These integrins are heterodimers and have large extracellular and short intracellular domains. ITGB1 interacts with various integrin alpha chains to form receptors for collagen, fibrinogen, fibronectin, osteopontin, VCAM1, and vitronectin among others. It is thought to play a role in endothelial motility and angiogenesis, thereby inciting an interest in tumor progression and cancer research. Additionally, ITGB1 is known to be involved in cell adhesion, invadopodia formation, and matrix degradation.
Invitrogen antibodies against ITGB1 are highly cited and tested for applications such as WB, IF, IHC, and ELISA. Specificity verification using techniques such as knockout via CRISPR-Cas9 genome editing further ensures that the antibody binds to the intended target. Figure 3 showcases two such antibodies for ITGB1 (Cat. No. MA5-13658 and MA1-81135), verified using CRISPR-Cas9 genome editing for immunofluorescence applications in HeLa cells.
Learn more about Invitrogen antibody validation
Search our entire inventory of Invitrogen antibodies using our antibody search tool
Figure 3. Antibodies against ITGB1 tested for specificity using CRISPR-Cas9– mediated knockout of ITGB1. Knockout of ITGB1 was achieved by CRISPR-Cas9 genome editing using the Invitrogen LentiArray Lentiviral sgRNA (Cat. No. A32042, Assay ID CRISPR626332_LV and CRISPR626355_LV) and the Invitrogen LentiArray Cas9 Lentivirus (Cat. No. A32064). Immunofluorescence (IF) analysis was performed on wild-type (WT) HeLa cells, Cas9-expressing HeLa cells, and HeLa ITGB1 knockout (KO) cells. (A) Cells were fixed, permeabilized, and labeled with the Invitrogen ITGB1 Monoclonal Antibody (clone 4B7R) (Cat. No. MA5-13658, 1:100 dilution), followed by the Invitrogen Goat Anti–Mouse IgG (H+L), Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 conjugate (Cat. No. A32723, 1:2,000, green). Nuclei (blue) were stained using the Invitrogen ProLong Diamond Antifade Mountant with DAPI (Cat. No. P36962), and Invitrogen Rhodamine Phalloidin (Cat. No. R415, 1:300) was used for cytoskeletal F-actin (red) staining. Loss of signal upon CRISPR-Cas9–mediated knockout confirms that the antibody is specific to ITGB1. (B) Cells were fixed, permeabilized, and labeled with the Invitrogen ITGB1 Monoclonal Antibody (clone JB1B) (Cat. No. MA1-81135, 1:100 dilution), followed by the Invitrogen Goat Anti–Mouse IgG (H+L), Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 conjugate (Cat. No. A32723, 1:2,000, green). Nuclei (blue) were stained using the Invitrogen ProLong Diamond Antifade Mountant with DAPI (Cat. No. P36962), and Invitrogen Rhodamine Phalloidin (Cat. No. R415, 1:300) was used for cytoskeletal F-actin (red) staining. Loss of signal upon CRISPR-Cas9–mediated knockout confirms that the antibody is specific to ITGB1. All images were captured at 60x magnification.
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine involved in inflammatory and immune responses. Although it was initially identified as a T cell–derived lymphokine that inhibited the random migration of macrophages, further studies have shown MIF to be ubiquitously expressed across different organs and tissues. MIF expresses in response to the immunosuppressive effects of glucocorticoids and counter-regulates the inhibition of inflammatory cytokines including TNF-α, IL-1, and IL-6 in macrophages and T lymphocytes. MIF secretion by macrophages is induced by endotoxins such as lipopolysaccharide (LPS) and is further elevated by cytokines including TNF-α and IFN-γ. Serum levels of MIF remain elevated 2–20 hours after LPS administration, which highlights the role of MIF in host inflammatory response.
Apart from its canonical role as an immunoregulator, MIF also plays a role in cell proliferation and differentiation, and its aberrant expression has been seen in many cancer tissues. MIF has also been shown to play a role in neovascularization, based on studies of lymphoma, melanoma, and colon cancer cells. A strong correlation of MIF expression exists with vascular endothelial growth factor (VEGF), the primary angiogenic factor in glioblastomas, suggesting the two may share co-regulatory pathways (Figure 4).
We are continually updating our Invitrogen primary antibody portfolio with advanced and verified products for use in flow cytometry (FC), immunohistochemistry (IHC), immunofluorescence (IF), immunocytochemistry (ICC), western blotting (WB), enzyme-linked immunosorbent assays (ELISAs), and other applications.
Learn more about Invitrogen antibody validation
Search our entire inventory of Invitrogen antibodies using our antibody search tool
Click image to enlarge
Click image to enlarge
Figure 4. Specificity of the MIF antibody observed when MIF is upregulated in response to VEGF treatment in the glioblastoma cell line U-87 MG.(A) Western blot (WB) analysis was performed using the Invitrogen MIF Monoclonal Antibody (clone 2Ar3) (Cat. No. MA1-20881), and a 15 kDa band corresponding to MIF was observed across cell lines tested. Upregulation of MIF expression was observed in U-87 MG cells after VEGF treatment (100 ng/mL for 48 hr). Whole cell extracts (30 μg lysate in all lanes) of the indicated cell lines were electrophoresed and transferred onto a nitrocellulose membrane, which was probed with the primary antibody (1 μg/mL) and detected by chemiluminescence with the Invitrogen Goat Anti–Mouse IgG (H+L), Superclonal Recombinant Secondary Antibody, HRP conjugate (Cat. No. A28177, 1:6,000 dilution), using the Invitrogen iBright FL1500 Imaging System (Cat. No. A44115). Chemiluminescent detection was performed using the Thermo Scientific Pierce ECL Western Blotting Substrate (Cat. No. 32106). (B) Immunofluorescence (IF) analysis using the Invitrogen MIF Polyclonal Antibody (Cat. No. PA5-81446, 1:100 dilution) shows upregulation of MIF expression in U-87 MG cells upon VEGF treatment. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Invitrogen Triton X-100 Solution (Cat. No. HFH10) for 15 minutes, and blocked with 2% BSA for 45 minutes at room temperature. The cells were labeled with the MIF Polyclonal Antibody (Cat. No. PA5-81446) at a 1:100 dilution in 0.1% BSA, incubated at 4°C overnight, and then labeled with the Invitrogen Donkey Anti–Rabbit IgG (H+L), Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 488 conjugate (Cat. No. A32790, 1:2,000 dilution), for 45 minutes at room temperature. Panel A: VEGF treated (green). Panel B: Nuclei stained with Invitrogen ProLong Diamond Antifade Mountant with DAPI (Cat. No. P36962, blue). Panel C: F-actin stained with Invitrogen Rhodamine Phalloidin (Cat. No. R415, 1:300, red). Panel D: Merged image showing cytoplasmic and secreted localization. Panel E: Untreated U-87 MG cells with lower expression level of MIF. Panel F: Control cells with no primary antibody to assess background. The images were captured at 60x magnification.
We now have a complete, comprehensive solution for researchers who want to investigate the 10 hallmarks of cancer using Invitrogen ProcartaPlex multiplex assays. With 46 additional targets and 6 extra panels, researchers can choose from any of these important hallmarks, including exosomal characterization, to perform cancer research.
Choose from the preconfigured panels shown below or design your own Mix & Match Oncology panel using the ProcartaPlex Panel Configurator
Learn more about our growing portfolio of ProcartaPlex immunoassays
Click image to enlarge
10 hallmarks of cancer with targets and Invitrogen ProcartaPlex panels identified.
Precise and accurate nucleic acid quantification is a critical step in many DNA and RNA research workflows. Success of downstream analyses (e.g., sequencing, PCR, transfection) often depend on the use of an appropriate amount of sample.
The Invitrogen Qubit Flex Fluorometer is a benchtop instrument designed for accurate and sensitive quantification of DNA, RNA, and protein samples. This one-of-a-kind instrument offers researchers the ability to measure up to 8 samples simultaneously. The updated instrument firmware (version 1.5.0) provides researchers with greater flexibility and functionality.
Enhanced firmware features:
- Flexibility to calibrate fewer than 8 wells—making the workflow faster for low-throughput users
- Fluorometer mode with blue or red excitation for users with custom assays
- Ability to export data as a PDF for customers requiring a non-editable results document
Download the updated firmware at thermofisher.com/qubitfirmware
Qubit Flex Fluorometer and Invitrogen Qubit 4 Fluorometer.
For Research Use Only. Not for use in diagnostic procedures.